Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

First patient dosed in global randomized, Phase 3 study in metastatic soft tissue sarcoma Collaboration agreement with The Swiss Group for Clinical Cancer Research SAKK ("SAKK") to conduct a Phase 2 randomized, study in early-stage breast cancer in Europe Cash and investments of $6.3 million expected to fund operations into the first quarter of 2025 SHELTON, Conn., Aug. 8, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology com ...